Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Parsaclisib in Combination with Rituximab, Bendamustine + Rituximab, or Ibrutinib in Patients with Previously Treated B-Cell Lymphoma: Analysis of a Phase 1 Dose-Finding Study (CITADEL-112)

Juan-Manuel Sancho, Pau Abrisqueta, Abhijeet Kumar, Raul Cordoba, Monica Tani, Teng Liu, Erica Rappold, Peter Langmuir, Armando Lopez-Guillermo

Blood (2022) 140 (Supplement 1): 9328–9330.

https://doi.org/10.1182/blood-2022-159703

Published: 2022

Journal Articles

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)

Tycel Phillips, Abraham Avigdor, Ronit Gurion, Caterina Patti, Paolo Corradini, Monica Tani, Amitkumar Mehta, Izidore S. Lossos, Pier Luigi Luigi Zinzani, Catherine Thieblemont, Wojciech Jurczak, Fred Zheng, Erica Rappold, Wanying Zhao, Peter Johnson

Blood (2021) 138 (Supplement 1): 44.

https://doi.org/10.1182/blood-2021-147778

Published: 2021

Journal Articles

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Tycel J. Phillips, MD, Paolo Corradini, Ronit Gurion, MD, Caterina Patti, MD, Monica Tani, MD, Abraham Avigdor, MD, Wojciech Jurczak, MD PhD, Amitkumar Mehta, MD, Pier Luigi Zinzani, MD, Izidore S. Lossos, MD, Catherine Thieblemont, MD PhD, Fred Zheng, MD, Erica Rappold, Wanying Zhao, Peter Johnson, MD FRCP

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-134451

Published: 2020